WARNING: This product contains non-tobacco-derived nicotine. Nicotine is an addictive chemical.

The Innovators

Mission

Kaival Labs upholds its commitment to provide a solution to tobacco-derived nicotine addiction.

VISION

Kaival Labs aims to see a tobacco-free future by fighting against smoke addiction through its groundbreaking patented science on R-S isomer alteration in nicotine, helping smokers pivot towards a tobacco-free life.

Kaival Labs uses clean, pure synthetic nicotine that is tobacco-free. Unlike others, our synthetic nicotine does not have any trace of tobacco; instead, it
was created from a natural starter that undergoes several chemical reactions until it produces the desired product.

Kaival Labs aims to provide synthetic nicotine to smoking cessation products that is devoid of impurities and carcinogenic components found in tobacco-derived nicotine.

NIRAJ PATEL
CEO, Kaival Labs
 

“Innovation is an attempt to solve the problem. We have been part of the industry long enough to be imperative in addressing tobacco nicotine addiction. Imagine a future without tobacco nicotine. What do you see? To us, it’s a more sustainable world with an improved quality of life, especially to those who are exposed to cigarettes and tobacco products. We want to take part in achieving this vision.”

Nirajkumar Patel, 35, is the CEO of Kaival Labs.  He attended AISSMS College of Pharmacy in Pune, India, and received a Bachelor of Science Degree in Pharmacy in 2004. After moving to the United States in 2005, Niraj finished his Master’s Degree in Chemistry from Florida Institute of Technology and earned a Six Sigma Black Belt Certification.

Niraj sees much potential in synthetic nicotine, which led him to establish Kaival Labs. The science behind the patent has discovered that the S-isomer controls the addictive qualities, whereas the R-isomer controls the beneficial attributes of the nicotine that a user enjoys. This patent’s uniqueness is that it allows Kaival Labs to control the levels of each isomer in the final synthetic nicotine molecule it produces

Because of Kaival Labs’ innovations, the synthetic nicotine used is certified clean, pure, and non-tobacco-derived. It can also be a potential key ingredient in numerous products, allowing the creation of entirely exclusive and patent-protected smoking cessation alternatives and nicotine addiction therapy. Some of these products are nicotine patches, lozenges, gums, vape sticks, e-liquids, and more, which are still useful and satisfying for the user but free from nicotine’s addictive traits. 

Billions of smokers and tobacco users worldwide are looking for an answer and a real solution to their nicotine addiction problems. Niraj imagines a world with patent-protected products, either approved pharmaceutically or made available over-the-counter that offer a way to truly ease users off of their addictive cravings for nicotine without losing any of their accustomed benefits. Through Kaival Labs, he channels this passion for developing these innovative patents and bringing effective, enjoyable smoking cessation products to an expanding market, helping all nicotine users lead healthier and higher-quality lives.

Message from the CEO

Innovation is an attempt to solve the problem. We have been part of the industry long enough to be imperative in addressing tobacco nicotine addiction. Imagine a future without tobacco nicotine. What do you see? To us, it’s a more sustainable world with an improved quality of life, especially to those who are exposed to cigarettes and tobacco products. We want to take part in achieving this vision. Niraj Patel, CEO of Kaival Labs, sees much potential with this synthetic nicotine from Kaival Labs. The science behind the patent has discovered that an S-isomer controls the addictive qualities of the nicotine, whereas an R-isomer controls the beneficial qualities of the nicotine that a user enjoys. The uniqueness of this patent is that it allows us to control the levels of each isomer in the final synthetic nicotine molecule we produce. This allows us to create completely exclusive and patent-protected products for smoking cessation and nicotine addiction therapy that are still effective and satisfying for the user, but free from nicotine’s addictive traits. Kaival Labs owns the patented science for pure yet non-addictive synthetic nicotine for the development of smoking cessation and Nicotine Replacement Therapy products. Tobacco-Free Nicotine (TFN) is a certified clean, pure, non-tobacco-derived synthetic nicotine, a key ingredient in numerous products like nicotine patches, lozenges, gums, vape sticks, e-liquids and more. Billions of smokers and tobacco users worldwide are looking for an answer and real solution to their nicotine addiction problems. Imagine patent-protected products, either approved pharmaceutically or made available over-the-counter, that offer a way to truly ease a user off their addictive cravings for nicotine without losing any of their accustomed benefits along the way. We are excited to develop these innovative patents and bring effective, enjoyable smoking cessation products to an expanding market, helping all nicotine users lead healthier and higher-quality lives.

ERIC MOSSER
Kaival Labs, COO

Eric Mosser, age 41, attended Arizona University and studied Business Management. He then graduated from Rio Salado College with an Associate’s Degree in Applied Science in Computer Technology in 2004.

Country

App Number
Patent Number

AUSTRALIA

2015335770
2015335770

CHINA

201580069647.2

EUROPE

1585 3179.8

INDIA

201727017843 334624

REPUBLIC OF KOREA

10-2016-7033978
10-1855611

PATENT COOPERATION TREATY

US2015/057017

USA

14/920796
9556142

Kaival Labs Stands Out

At the very core of Kaival Labs is breakthrough research that allow us to continuously evolve and improve our product. Through these new innovations, smokers will have access to more tobacco nicotine alternatives and steer them away from cigarettes